Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.73 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.73 |
| ▸ | HSP90B1 | P14625 | 5/20 | 0.51 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219414 | 1.00 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1745946 | 1.00 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1219900 | 0.89 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1219903 | 0.89 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1219824 | 0.88 | HSP90AA1 (0.93) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220481 | 0.88 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220476 | 0.88 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220353 | 0.87 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220356 | 0.87 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5148446 | 0.87 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-07-28 | — | — | US | claimed |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | ESANEX, INC. | 2006-09-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | HSF1, HSPA4, HSP90AB1 | HSP90AA1 4/4885HSP90AB1 3/4885HSP90B1 23/4885 |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | HSP90AA1 3912/4885HSP90AB1 3419/4885HSP90B1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.